Files in This Item:
   
Thumbnail13_5_2007_1053_1059.pdf

View/Open

Title: High-dose deferoxamine treatment [intravenous] for thalassaemia patients with cardiac complications
Authors: Ghader, F.R.
Kousarian, M.
Farzin, D.
Issue Date: 2007
Language: English
Abstract: As a means to manage cardiac conditions, we determined the effects of high-dose intravenous [IV] deferoxamine in 15 thalassaemia patients with cardiomyopathy and high ferritin and haemoglobin levels. The patients received IV deferoxamine, 130 mg/kg per day over 10-14 hours [maximum 5 g] for 5 consecutive days. All patients underwent a full evaluation before receiving deferoxamine, and 2 days and 1 month after completing the treatment. Visual and auditory examinations were done to detect any side-effects. After treatment, cardiovascular symptoms decreased considerably and systolic function showed significant improvement, but there was no significant effect on diastolic function, electro-cardiography and physical findings. There were no significant side-effects reported
Description: 1053-1059
Keywords: Deferoxamine
Thalassemia
Treatment Outcome
Cardiomyopathies
Ferritins
Subject: Deferoxamine
URI: http://www.who.int/iris/handle/10665/117346
ISSN: 1020-3397
Other Identifiers: http://applications.emro.who.int/emhj/1305/13_5_2007_1053_1059.pdf
Appears in Collections:EMRO Journal Articles (EMHJ)



Items in WHO IRIS are protected by copyright, with all rights reserved, unless otherwise indicated.